Show simple item record

dc.contributor.authorBartlett, FR
dc.contributor.authorDonovan, EM
dc.contributor.authorMcNair, HA
dc.contributor.authorCorsini, LA
dc.contributor.authorColgan, RM
dc.contributor.authorEvans, PM
dc.contributor.authorMaynard, L
dc.contributor.authorGriffin, C
dc.contributor.authorHaviland, JS
dc.contributor.authorYarnold, JR
dc.contributor.authorKirby, AM
dc.date.accessioned2017-03-09T14:27:40Z
dc.date.issued2017-03
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2017, 29 (3), pp. e51 - e56
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/482
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2016.11.005
dc.description.abstractAims To evaluate the feasibility and heart-sparing ability of the voluntary breath-hold (VBH) technique in a multicentre setting.Materials and methods Patients were recruited from 10 UK centres. Following surgery for early left breast cancer, patients with any heart inside the 50% isodose from a standard free-breathing tangential field treatment plan underwent a second planning computed tomography (CT) scan using the VBH technique. A separate treatment plan was prepared on the VBH CT scan and used for treatment. The mean heart, left anterior descending coronary artery (LAD) and lung doses were calculated. Daily electronic portal imaging (EPI) was carried out and scanning/treatment times were recorded. The primary end point was the percentage of patients achieving a reduction in mean heart dose with VBH. Population systematic (Σ) and random errors (σ) were estimated. Within-patient comparisons between techniques used Wilcoxon signed-rank tests.Results In total, 101 patients were recruited during 2014. Primary end point data were available for 93 patients, 88 (95%) of whom achieved a reduction in mean heart dose with VBH. Mean cardiac doses (Gy) for free-breathing and VBH techniques, respectively, were: heart 1.8 and 1.1, LAD 12.1 and 5.4, maximum LAD 35.4 and 24.1 (all P<0.001). Population EPI-based displacement data showed Σ =+1.3-1.9 mm and σ=1.4-1.8 mm. Median CT and treatment session times were 21 and 22 min, respectively.Conclusions The VBH technique is confirmed as effective in sparing heart tissue and is feasible in a multicentre setting.
dc.formatPrint-Electronic
dc.format.extente51 - e56
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectLung
dc.subjectCoronary Vessels
dc.subjectHeart
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectTomography, X-Ray Computed
dc.subjectRadiotherapy Dosage
dc.subjectRadiotherapy Planning, Computer-Assisted
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectOrgans at Risk
dc.subjectBreath Holding
dc.titleThe UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy.
dc.typeJournal Article
dcterms.dateAccepted2016-10-06
rioxxterms.versionofrecord10.1016/j.clon.2016.11.005
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue3
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume29
pubs.embargo.terms12 months
icr.researchteamClinical Trials & Statistics Uniten_US
icr.researchteamBreast Cancer Radiotherapyen_US
dc.contributor.icrauthorMcNair, Helenen
dc.contributor.icrauthorGriffin, Clareen
dc.contributor.icrauthorKirby, Annaen
dc.contributor.icrauthorYarnold, Johnen
dc.contributor.icrauthorHaviland, Joanneen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record